HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist being investigated to treat a wide range of solid…
September 11, 2025 09:00 ET | Source: Nacuity Pharmaceuticals, Inc. NPI-001 shows more than 50% reduction in photoreceptor loss caused…
SCOTTSDALE, Ariz., Sept. 10, 2025 /PRNewswire/ -- Imaging Endpoints (IE), the global leader in Imaging CRO technologies and services for…
Medidata eCOA was the highest Leader recognized in the evaluation, supporting over 1M+ patients and reducing study build timeline by…
WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory…
ZUG, Switzerland, Sept. 1, 2025 /PRNewswire/ -- Berlin Heals Holding AG, a MedTech company, is developing a novel treatment to…
- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society…
Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol Primary Endpoint Result Consistent Across All Prespecified Subgroups Company to…
August 21, 2025 01:30 ET | Source: NICOX SA Press Release Nicox Announces Positive Results from the NCX 470 Phase…
Garching / Munich, Germany, August 19, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced…